Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo
Duration of treatment effect · glabellar lines
1 finding from 1 review
- no estimate extracted1 study · 77 participantsModerate
Findings
What do systematic reviews say?
4,703 questions · 15,007 findings · 1,416 reviews
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Participant assessment of success by analysing scores and scales ‐ 20 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U leads to higher participant assessment of success by analysing scores and scales ‐… compared with placebo (high certainty).
1 finding from 1 review
- RR 5.33 [1.67, 16.99]1 study · 300 participantsHigh
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 3.36 [0.88, 12.87]7 studies · 1294 participantsModerate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Physician assessment of success · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 15.78 [8.75, 28.45]7 studies · 1060 participantsModerate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Total adverse events · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.25 [1.05, 1.49]8 studies · 1471 participantsLow
NSAIDs vs placebo
Adequate pain relief as reported by women · women with perineal pain in the early postpartum period
NSAID may leads to higher adequate pain relief(4 hours after administration) compared with placebo (low certainty).
2 findings from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyRR 1.91 [1.64, 2.23]10 studies · 1573 participantsLow
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyRR 1.92 [1.69, 2.17]17 studies · 2079 participantsVery low
NSAIDs vs placebo
Need for additional analgesia (4 hours after administration) · women with perineal pain in the early postpartum period
NSAID probably leads to lower need for additional analgesia(4 hours after administration) compared with placebo (moderate certainty).
1 finding from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyRR 0.39 [0.26, 0.58]4 studies · 486 participantsModerate
NSAIDs vs placebo
Need for additional analgesia (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID changes need for additional analgesia (6 hours after administration) compared with placebo (very low certainty).
1 finding from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyRR 0.32 [0.26, 0.4]10 studies · 1012 participantsVery low
NSAIDs vs placebo
Maternal drug adverse effects(4 hours after administration) · women with perineal pain in the early postpartum period
1 finding from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 90 participantsGRADE not reported
NSAIDs vs placebo
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID showed no clear difference in maternal drug adverse effects(6 hours after administration) compared with placebo (low certainty).
1 finding from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyRR 1.38 [0.71, 2.7]13 studies · 1388 participantsLow
NSAIDs vs placebo
Neonatal drug adverse effects · women with perineal pain in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
- Oral non‐steroidal anti‐inflammatory drugs (single dose) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Heparin vs placebo
Early graft thrombosis · kidney transplant recipients
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Heparin vs placebo
Major bleeding events: unfractionated heparin · kidney transplant recipients
Heparin showed no clear difference in major bleeding events: unfractionated heparin compared with placebo (low certainty).
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyRR 2.92 [0.89, 9.56]3 studies · 155 participantsLow
Heparin vs placebo
Major bleeding events: all heparin · kidney transplant recipients
Heparin showed no clear difference in major bleeding events: all heparin compared with placebo (low certainty).
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyRR 2.7 [0.89, 8.19]3 studies · 180 participantsLow
Heparin vs placebo
Readmissions to intensive care: all heparin · kidney transplant recipients
It is very uncertain whether heparin changes readmissions to intensive care: all heparin compared with placebo (very low certainty).
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyRR 0.68 [0.12, 3.9]3 studies · 180 participantsVery low
Heparin vs placebo
Blood transfusion requirements · kidney transplant recipients
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Heparin vs placebo
Graft and patient survival · kidney transplant recipients
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Heparin vs placebo
Non‐graft thrombosis · kidney transplant recipients
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Vitamin D vs placebo or no intervention
All‐cause mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- Vitamin D supplementation for chronic liver diseases in adults 2021 · Cochrane Headline outcomes onlyRR 0.86 [0.51, 1.45]27 studies · 1979 participantsVery low
Vitamin D vs placebo or no intervention
Liver‐related mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes liver‐related mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- Vitamin D supplementation for chronic liver diseases in adults 2021 · Cochrane Headline outcomes onlyRR 1.62 [0.08, 34.66]1 study · 18 participantsVery low